Ainos, Inc. (AIMD)
NASDAQ: AIMD · Real-Time Price · USD
2.390
-0.110 (-4.40%)
At close: Dec 5, 2025, 4:00 PM EST
2.450
+0.060 (2.51%)
After-hours: Dec 5, 2025, 6:59 PM EST

Company Description

Ainos, Inc., a dual-platform AI and biotech company, focusing SmellTech, AI diagnostics, and immune therapeutics.

Its AI Nose platform uses a smell language model to digitize scent into Smell IDs and turning invisible chemical signals into machine-readable data.

The company is also giving AI for robotics, smart factories, senior care, and women’s health. In addition, it develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases, plus applications in animal health.

The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021.

Ainos, Inc. was incorporated in 1984 and is based in San Diego, California. Ainos, Inc. is a subsidiary of Taiwan Carbon Nano Technology Corporation.

Ainos, Inc.
Ainos logo
Country United States
Founded 1984
Industry Scientific & Technical Instruments
Sector Technology
Employees 44
CEO Chun-Hsien Tsai

Contact Details

Address:
8880 Rio San Diego Drive, Suite 800
San Diego, California 92108
United States
Phone 858 869 2986
Website ainos.com

Stock Details

Ticker Symbol AIMD
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001014763
CUSIP Number 00902F402
ISIN Number US00902F4028
Employer ID 75-1974352
SIC Code 2834

Key Executives

Name Position
Chun-Hsien Tsai Chief Executive Officer, President and Chairman of the Board
Hsin-Liang Lee Chief Financial Officer
Chih-Heng Lu Director of Corporate Developoment

Latest SEC Filings

Date Type Title
Nov 28, 2025 SCHEDULE 13D/A Filing
Nov 28, 2025 SCHEDULE 13D Filing
Nov 28, 2025 SCHEDULE 13D/A Filing
Nov 28, 2025 SCHEDULE 13D/A Filing
Nov 13, 2025 10-Q Quarterly Report
Nov 13, 2025 8-K Current Report
Oct 17, 2025 8-K Current Report
Oct 9, 2025 SCHEDULE 13D/A Filing
Oct 9, 2025 SCHEDULE 13D/A Filing
Oct 1, 2025 DEF 14A Other definitive proxy statements